
Matteo Lambertini: Adjuvant Endocrine Therapy in HR+ Breast Cancer
Matteo Lambertini, Associate Professor at the University of Genova, shared a post on LinkedIn:
“Published in The Lancet Group the meta-analysis on individual data that clarifies the indications on the extension of adjuvant endocrine therapy in patients with early hormone receptor positive breast cancer… great contribution of Italian academic research GIM coordinated by the super Prof. Lucia Del Mastro of Università degli Studi di Genova, Ospedale Policlinico San Martino!”
Title: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
Author: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
More posts featuring Matteo Lambertini on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023